文献速递妇科生殖医学

子宫内膜异位症术后激素抑制与复发风险:系统综述与荟萃分析

Endometriosis recurrence following post-operative hormonal suppression: a systematic review and meta-analysis.
PubMed 文献 · Hum Reprod Update · 2021-01-01

该系统综述与荟萃分析纳入17项研究共2137例患者,评估术后激素抑制对子宫内膜异位症复发的影响。结果显示激素抑制组复发风险显著低于对照组(RR 0.41,95%CI 0.26-0.65),疼痛评分也显著降低(SMD -0.49,95%CI -0.91至-0.07)。作者建议术后不考虑立即妊娠的患者应考虑激素抑制。

要点

  • 术后激素抑制显著降低复发风险(RR 0.41,95%CI 0.26-0.65)。
  • 激素抑制组疼痛评分显著低于对照组(SMD -0.49,95%CI -0.91至-0.07)。
  • 复方口服避孕药和左炔诺孕酮宫内系统亚组分析显示一致的复发风险降低。

核心结论

  • 术后激素抑制可显著降低子宫内膜异位症复发风险和疼痛评分,建议术后不立即妊娠的患者考虑使用。

研究设计与样本

  • 系统综述与荟萃分析,纳入17项研究(13项RCT和4项队列研究),共2137例患者(激素抑制组1189例,对照组948例)。

主要发现

  • 激素抑制组复发风险显著低于对照组(RR 0.41,95%CI 0.26-0.65,14项研究,1766例患者,I2=68%)。
  • 激素抑制组疼痛评分显著低于对照组(SMD -0.49,95%CI -0.91至-0.07,7项研究,652例患者,I2=68%)。
  • 复方口服避孕药和左炔诺孕酮宫内系统亚组分析及仅限RCT和高质量研究的敏感性分析显示一致的复发风险降低。

关键数值与推荐

  • 纳入标准:绝经前女性,保守手术(至少保留一侧卵巢),术后6周内开始激素抑制(复方激素避孕药、孕激素、雄激素、左炔诺孕酮宫内系统或GnRH激动剂/拮抗剂)。
  • 排除标准:随访<12个月、诊断性腹腔镜、实验性/非激素治疗或联合激素治疗。
  • 主要结局:术后至少12个月通过影像学或症状复发确定的子宫内膜异位症复发。
  • 次要结局:子宫内膜异位症相关疼痛变化。
  • 平均随访12至36个月,结局评估中位时间18个月。

临床怎么用

  • 对于子宫内膜异位症术后不寻求立即妊娠的患者,应考虑术后激素抑制以减少疾病复发和疼痛。
  • 激素抑制药物的选择应根据每位女性的需求个体化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although surgery for endometriosis can improve pain and fertility, the risk of disease recurrence is high. There is little consensus regarding the benefit of medical therapy in preventing recurrence of endometriosis following surgery. OBJECTIVE AND RATIONALE: We performed a review of prospective observational studies and randomised controlled trials (RCTs) to evaluate the risk of endometriosis recurrence in patients undergoing post-operative hormonal suppression, compared to placebo/expectant management. SEARCH METHODS: The following databases were searched from inception to March 2020 for RCTs and prospective observational cohort studies: MEDLINE, Embase, Cochrane CENTRAL and Web of Science. We included English language full-text articles of pre-menopausal women undergoing conservative surgery (conserving at least one ovary) and initiating hormonal suppression within 6 weeks post-operatively with either combined hormonal contraceptives (CHC), progestins, androgens, levonorgesterel-releasing intra-uterine system (LNG-IUS) or GnRH agonist or antagonist. We excluded from the final analysis studies with <12 months of follow-up, interventions of diagnostic laparoscopy, experimental/non-hormonal treatments or combined hormonal therapy. Risk of bias was assessed using the Cochrane Risk of Bias Tool for RCTs and the Newcastle-Ottawa Scale (NOS) for observational studies. OUTCOMES: We included 17 studies (13 RCTs and 4 cohort studies), with 2137 patients (1189 receiving post-operative suppression and 948 controls), which evaluated various agents: CHC (6 studies, n = 869), progestin (3 studies, n = 183), LNG-IUS (2 studies, n = 94) and GnRH agonist (9 studies, n = 1237). The primary outcome was post-operative endometriosis recurrence, determined by imaging or recurrence of symptoms, at least 12 months post-operatively. The secondary outcome was change in endometriosis-related pain. Mean follow up of included studies ranged from 12 to 36 months, and outcomes were assessed at a median of 18 months. There was a significantly decreased risk of endometriosis recurrence in patients receiving post-operative hormonal suppression compared to expectant management/placebo (relative risk (RR) 0.41, 95% CI: 0.26 to 0.65), 14 studies, 1766 patients, I2 = 68%, random effects model). Subgroup analysis on patients treated with CHC and LNG-IUS as well as sensitivity analyses limited to RCTs and high-quality studies showed a consistent decreased risk of endometriosis recurrence. Additionally, the patients receiving post-operative hormonal suppression had significantly lower pain scores compared to controls (SMD -0.49, 95% CI: -0.91 to -0.07, 7 studies, 652 patients, I2 = 68%). WIDER IMPLICATIONS: Hormonal suppression should be considered for patients not seeking pregnancy immediately after endometriosis surgery in order to reduce disease recurrence and pain. Various hormonal agents have been shown to be effective, and the exact treatment choice should be individualised according to each woman's needs.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Zakhari A, Delpero E, McKeown S, et al. Endometriosis recurrence following post-operative hormonal suppression: a systematic review and meta-analysis. Hum Reprod Update. 2021. PMID: 33020832. doi:10.1093/humupd/dmaa033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。